Genentech joins forces with Affimed, a German cancer company, to create new treatments for various solid and blood cancers. Affimed is developing therapies that boost the body's natural killer cells to go after cancer cells. In this collaboration, Genentech will pay Affimed $96 million upfront and can provide up to$5 billion more based on progress.